Stereotaxis Inc (STXS)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX
Market Cap: $80.94M
Last updated: Nov 17, 2026 at 4:20 PM ET
Stereotaxis Inc (STXS) Statistics
Stereotaxis (STXS) has a market cap of $80.94M and an enterprise value of $84.28M. It kept -70.86% of revenue as net income over the last 12 months. Its share count is up 11.45% from a year earlier.
Total Valuation
Enterprise value is 4.14% above the market cap, as debt exceeds cash.
| Market Cap | $80.94M |
|---|---|
| Enterprise Value | $84.28M |
| Latest price (Nov 17, 2026) | $0.90 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.9x and 4.3x. Its year-end P/S ranged from 0.4x to 110.5x from 2016 to 2025.
| P/S Ratio | 2.9x |
|---|---|
| Forward P/S | 2.6x |
| P/B Ratio | 4.3x |
Price Statistics
The stock is down 59.66% over 52 weeks and trades 18.92% below its 50-day average.
| Beta (1Y) | 1.19 |
|---|---|
| 52-Week Change | -59.66% |
| 1-Month Change | -11.33% |
| 3-Month Change | -35.10% |
| 6-Month Change | -48.23% |
| 5-Year Change | -85.38% |
| 10-Year Change | +23.23% |
| Total Return (1Y) | -59.66% |
| Total Return (3Y CAGR) | -16.88% |
| Total Return (5Y CAGR) | -32.77% |
| Max Drawdown (1Y) | -71.23% |
| Max Drawdown (3Y) | -77.52% |
| Sharpe Ratio (1Y) | -1.71 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $1.11 |
| 200-Day Average | $1.61 |
| 52-Week Range | $0.80 to $2.86 |
| RSI (14 Days) | 42.7 |
| Average Volume (20 Days) | 991.25K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.08x current liabilities, and total debt is 0.34x shareholder equity.
| Current Ratio | 1.08x |
|---|---|
| Quick Ratio | 0.67x |
| Debt / Equity | 0.34x |
| Interest Coverage | 75.82x |
Returns and Efficiency
Return on invested capital is -62.43% over the last 12 months, against a 5-year average of -95.06%.
| Return on Equity (ROE) | -104.60% |
|---|---|
| Return on Assets (ROA) | -27.21% |
| Return on Invested Capital (ROIC) | -62.43% |
| ROA (5Y Average) | -38.82% |
| ROIC (5Y Average) | -95.06% |
| Asset Turnover | 0.49x |
| Inventory Turnover | 1.16x |
| Receivables Turnover | 4.80x |
| Cash Conversion Cycle | 213 days |
Scores
STXS has an Altman Z-Score of -9.73, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.73 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $31.53M over the last 12 months is up 4.84% from the 12 months before.
| Revenue | $31.53M |
|---|---|
| Revenue Growth (YoY) | +4.84% |
| Gross Profit | $16.56M |
| Operating Income | -$22.67M |
| Pretax Income | -$22.34M |
| Net Income | -$22.34M |
| EBITDA | -$20.97M |
| Reported EPS (TTM) | -$0.24 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 26.01% of the $82.11M in total assets.
| Cash and Equivalents | $3.98M |
|---|---|
| Total Debt | $7.32M |
| Net Debt | $3.35M |
| Net Debt Per Share | $0.03 |
| Working Capital | $2.68M |
| Shareholder Equity | $21.36M |
| Book Value Per Share | $0.21 |
| Tangible Book Value | -$14.90M |
| Total Assets | $82.11M |
| Total Liabilities | $55.58M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $240.00K of capital spending, operating cash flow left -$15.50M of free cash flow.
| Operating Cash Flow | -$15.26M |
|---|---|
| Capital Expenditures | $240.00K |
| Free Cash Flow | -$15.50M |
| FCF Per Share | -$0.15 |
| Depreciation and Amortization | $1.70M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -71.90%, against a 5-year average of -69.06%.
| Gross Margin | 52.53% |
|---|---|
| Operating Margin | -71.90% |
| Pretax Margin | -70.84% |
| Net Margin | -70.86% |
| EBITDA Margin | -66.51% |
| FCF Margin | -49.17% |
| Gross Margin (5Y Average) | 58.88% |
| Operating Margin (5Y Average) | -69.06% |
| Net Margin (5Y Average) | -65.83% |
Growth
Revenue grew 4.78% a year over 3 years.
| Revenue Growth (3Y CAGR) | +4.78% |
|---|---|
| Revenue Growth (5Y CAGR) | +3.99% |
| Book Value Per Share Growth (2Y CAGR) | -15.69% |
| Tangible Book Per Share Growth (2Y CAGR) | -58.36% |
Dividends and Yields
STXS does not pay a dividend. Its free cash flow yield is -16.88%.
| FCF Yield | -16.88% |
|---|---|
| Buyback Yield | -15.34% |
| Shareholder Yield | -15.34% |
Stock Splits
The last split was a 1-for-10 reverse split on Jul 11, 2012.
| Last Split Date | Jul 11, 2012 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 11 similar companies, STXS has the 5th highest P/S.
P/S RatioPeer median 2.6x
ROICPeer median 6.74%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.82%
| P/S Ratio | 2.9x vs 2.6x median |
|---|---|
| ROIC | -62.43% vs 6.74% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4.84% vs +9.82% median |
Analyst Forecast
Consensus estimates put revenue growth at 11.43% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +11.43% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About STXS
What is STXS's market cap?
Stereotaxis has a market cap of $80.94M. Its enterprise value, which adds debt and subtracts cash, is $84.28M.
How many shares of STXS are outstanding?
Stereotaxis has 102.55M shares outstanding. The count is up 11.45% from a year earlier.
Does STXS pay a dividend?
No. Stereotaxis does not pay a dividend.
How much debt does STXS have?
Stereotaxis has $7.32M of total debt and $3.98M of cash and equivalents, a net debt position of $3.35M.
STXS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors